Alpha Compute Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Brittany Kaiser

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	less than a year

Actualizaciones recientes de la dirección

Recent updates

Seeking Alpha • Aug 29

Portage Biotech GAAP EPS of -$0.13

Portage Biotech press release (NASDAQ:PRTG): Q1 GAAP EPS of -$0.13. As of June 30, 2022, the Company had cash and cash equivalents of approximately $21.2 million.

Seeking Alpha • Jul 20

Portage Biotech rises after getting full ownership of its anti-cancer agonist platform

Portage Biotech (NASDAQ:PRTG) stock has added 16.8% to $10.95 in Wednesday morning trading, after the company said it had acquired the remaining ownership interest in its invariant natural killer T cell (iNKT cell) agonist platform. iNKT cells play an important role in anti-tumor immune responses. PRTG's synthetic iNKT agonists activate and expand important immune system components and immune attacks against cancer. With the acquisition of the about 22% remaining ownership interest, PRTG now fully owns the worldwide rights to its iNKT agonists, including lead programs PORT-2 and PORT-3. The acquisition was done through PRTG's unit iOx Therapeutics from the founding equity holders in exchange for 1.07M shares of Portage (PRTG). Additionally, a payment of $25M in PRTG shares or cash would be triggered upon the achievement of a certain clinical milestone in the PORT-2 or PORT-3 programs.

Seeking Alpha • Jul 06

Portage Biotech acquires Tarus Therapeutics, a developer of adenosine receptor antagonists

Portage Biotech (NASDAQ:PRTG) on Wednesday said it would acquire privately-held Tarus Therapeutics in exchange for about 2.4M PRTG shares and the assumption of $3M in liabilities. The acquisition of Tarus allows PRTG to acquire two clinical-stage adenosine compounds and two preclinical assets for a ~$21M upfront consideration. The deal also calls for additional payments of up to $32M in PRTG shares or cash upon achievement of certain milestones. As per the deal, Robert Glassman, a former independent director of Tarus, will join PRTG's board. PRTG also said it had entered into a committed share purchase agreement for up to $30M with Chicago-based institutional investor Lincoln Park Capital Fund LLC, the proceeds of which will potentially extend PRTG's cash runway into 2024. PRTG stock earlier closed +2.5% at $7.72.

CEO

Brittany Kaiser (36 yo)

less than a year

Permanencia

Ms. Brittany Kaiser has been a Member of the Advisory Board of Hamak Strategy Limited (formerly known as Hamak Gold Limited) since September 11, 2025. She serves as CEO & Director at Alpha Compute Corp (fo...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Kramer	Chief Scientific Officer	7.3yrs	US$119.25k	0.021% $ 1.4k
Fiorenzo Villani	Executive Chairman & Chief Investment Officer	less than a year	sin datos	sin datos
Brittany Kaiser	CEO & Director	less than a year	sin datos	sin datos
Wesley Levitt	Chief Financial Officer	less than a year	sin datos	sin datos
Logan Golema	Chief Technology Officer	less than a year	sin datos	sin datos
William De'Ath	Chief Partnership Officer	less than a year	sin datos	sin datos
Adam Melero	Controller	1.7yrs	sin datos	sin datos
Peter Molloy	Chief Executive Officer of Cyncado Therapeutics Inc.	1.3yrs	sin datos	sin datos

0.7yrs

Permanencia media

45.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ALP no se considera experimentado ( 0.7 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Fiorenzo Villani	Executive Chairman & Chief Investment Officer	less than a year	sin datos	sin datos
Brittany Kaiser	CEO & Director	less than a year	sin datos	sin datos
Jean-Christophe Renondin	Director	2.1yrs	US$126.99k	0% $ 0
Gregory Bailey	Independent Lead Director	12.9yrs	US$30.00k	2.13% $ 134.5k
James Mellon	Independent Director	4.3yrs	US$30.00k	1.15% $ 72.9k
F. Siciliano	Director	less than a year	sin datos	sin datos
Tom Richer	Member of Advisory Board	less than a year	sin datos	sin datos

0.8yrs

Permanencia media

59yo

Promedio de edad

Junta con experiencia: La junta directiva de ALP no se considera experimentada (0.8 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/05/07 02:01
Precio de las acciones al final del día	2026/05/07 00:00
Beneficios	2025/09/30
Ingresos anuales	2025/03/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Alpha Compute Corp está cubierta por 4 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Justin Walsh	B. Riley Securities, Inc.
Li Wang Watsek	Cantor Fitzgerald & Co.
Kevin Dede	H.C. Wainwright & Co.

Alpha Compute Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Alpha Compute Corp. Appoints Tom Richer to Advisory Board

Less than half of directors are independent

AlphaTON Capital Corp. Announces Board Changes, Effective February 6, 2026

AlphaTON Capital Corp. Announces the Appointment of Logan Ryan Golema as Chief Technology Officer

AlphaTON Capital Corp. Appoints William De’Ath as Chief Partnership Officer

AlphaTON Capital Corp. Appoints Wes Levitt as Chief Financial Officer, October 24, 2025

Recent updates

Alpha Compute Confirms That Its First Large-Scale GPU Cluster Is Now in Final Testing and Is Targeted to Hand over to AI Compute Customers on May 8, 2026

Alpha Compute Corp. Appoints Tom Richer to Advisory Board

AlphaTON Capital Corp. announced that it expects to receive $43 million in funding from Vertical Data Inc.

AlphaTON Capital Corp. has filed a Follow-on Equity Offering in the amount of $400 million.

Less than half of directors are independent

AlphaTON Capital Corp. Announces Board Changes, Effective February 6, 2026

AlphaTON Capital Corp. Launches Claude Connector Powered by TON & Telegram

AlphaTON Capital Corp. has completed a Follow-on Equity Offering in the amount of $14.999023 million.

AlphaTON Capital Corp. has filed a Follow-on Equity Offering in the amount of $14.999023 million.

New major risk - Market cap size

AlphaTON Capital Corp. Announces the Appointment of Logan Ryan Golema as Chief Technology Officer

Cyncado Therapeutics and Tarus Therapeutics, Llc Announces A Non-Binding Letter of Intent (Loi)

AlphaTON Capital Corp. Appoints William De’Ath as Chief Partnership Officer

Tarus Therapeutics, LLC Announces A Poster Presentation At the Society for Immunotherapy of Cancer Annual Meeting

AlphaTON Capital Corp and Tarus Therapeutics, LLC Announces Preclinical Mesothelioma Data Show Direct A2b Tumor Activity

AlphaTON Capital Corp. Appoints Wes Levitt as Chief Financial Officer, October 24, 2025

AlphaTON Capital Corp and Cyncado Therapeutics Announce First Evidence That Selective A2b Receptor Inhibition Lowers Pd-L1 Tumor Expression and Directly Suppresses Mesothelioma Tumor Growth

Alphaton Capital Corp. Launches Ai Vertical with Morpheusai to Accelerate Agentic Ai Development on Ton and Telegram

New major risk - Share price stability

AlphaTON Capital Corp. (NasdaqCM:ATON) entered into a non-binding letter of intent to acquire 51% stake in Gamee Limited from Animoca Brands Limited.

AlphaTON Capital Corp. announced that it has received $36.2136 million in funding

Less than half of directors are independent

Portage Biotech Inc. has filed a Follow-on Equity Offering in the amount of $2.84145 million.

New major risk - Negative shareholders equity

Portage Biotech Inc. has filed a Follow-on Equity Offering in the amount of $3.37725 million.

New major risk - Market cap size

Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of Port-7

Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial

New major risk - Shareholder dilution

Portage Biotech Receives Extension of Time to Attain Compliance with Stock Exchange Continued Listing Requirements

Portage Biotech Inc. Appoints Peter Molloy as CEO of Subsidiary, Cyncado Therapeutics, Inc

New major risk - Revenue and earnings growth

Less than half of directors are independent

Portage Biotech Inc. Appoints Alexander Pickett as Chief Executive Officer, Effective December 15, 2024

Portage Biotech Inc. Appoints Alexander Pickett to Board of Directors, Effective December 15, 2024

Price target decreased by 22% to US$140

Portage Biotech Inc. Announces Chief Financial Officer Changes

Portage Biotech Inc. announced delayed 20-F filing

Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives

New major risk - Financial position

New major risk - Market cap size

Portage Biotech Inc. Presents Updates on its iNKT and Adenosine Programs at the Society for Immunotherapy of Cancer's 38th Annual Meeting

New major risk - Revenue and earnings growth

New major risk - Share price stability

Price target decreased by 16% to US$16.00

Portage Biotech Inc. Announces First Patient Dosed in Phase 1A Trial of Portage-6 in Select Solid Tumors

Portage Biotech Reports Updated Interim Data for Lead Inkt Engager, Port-2, in A Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer At the 2023 American Society for Clinical Oncology (Asco) Annual Meeting

Portage Biotech Inc. Presents Updated Data on the Phase 1/2 Trial Evaluating Port-2 At the Society for Immunotherapy of Cancer’S (Sitc) 37Th Annual Meeting

Portage Biotech Inc., Annual General Meeting, Nov 10, 2022

Portage Biotech Inc. Provides Research and Development Update

Portage Biotech GAAP EPS of -$0.13

Portage Biotech Inc. Announces Leadership Updates

Portage Biotech rises after getting full ownership of its anti-cancer agonist platform

Portage Biotech Inc. (NasdaqCM:PRTG) signed an agreement to acquire Tarus Therapeutics, Inc. for $53.3 million.

Robert Glassman to Join Portage Biotech Inc. Board of Directors

Portage Biotech acquires Tarus Therapeutics, a developer of adenosine receptor antagonists

Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting

Portage Biotech Inc. Provides an Update on Its Clinical Development Programs and Announces Its Development Goals for the Remainder of 2022

Portage Biotech Announces Executive Changes

Portage Biotech Inc. Highlights First Patient Dosed in Imp-Mel Study of Port-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (Nsclc)

Portage Biotech Inc. has completed a Follow-on Equity Offering in the amount of $23 million.

Portage Biotech Inc. Highlights Safety and Survival Data from Intensity Therapeutics' It-01 Study of Int230-6 (Port-1) At Asco 2021 Annual Meeting

Juvenescence Ltd. acquired Portage pharmaceuticals Ltd from Portage Biotech Inc. (NasdaqCM:PRTG).

Portage Biotech's Common Shares Deleted from Other OTC

Portage Biotech Inc. announced that it has received $6.98145 million in funding

Portage Biotech Inc. announced that it has received $6.7886 million in funding

CEO

Equipo directivo

Miembros de la Junta